GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Monte Rosa Therapeutics Inc (NAS:GLUE) » Definitions » Market Cap

Monte Rosa Therapeutics (Monte Rosa Therapeutics) Market Cap : $243.38 Mil (As of Jun. 09, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Monte Rosa Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Monte Rosa Therapeutics's share price for the quarter that ended in Mar. 2024 was $7.05. Monte Rosa Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 50.20 Mil. Therefore, Monte Rosa Therapeutics's market cap for the quarter that ended in Mar. 2024 was $353.91 Mil.

Monte Rosa Therapeutics's quarterly market cap increased from Sep. 2023 ($239.81 Mil) to Dec. 2023 ($283.29 Mil) and increased from Dec. 2023 ($283.29 Mil) to Mar. 2024 ($353.91 Mil).

Monte Rosa Therapeutics's annual market cap declined from Dec. 2021 ($950.27 Mil) to Dec. 2022 ($375.35 Mil) and declined from Dec. 2022 ($375.35 Mil) to Dec. 2023 ($283.29 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Monte Rosa Therapeutics's Enterprise Value for Today is $95.67 Mil.


Monte Rosa Therapeutics Market Cap Historical Data

The historical data trend for Monte Rosa Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Monte Rosa Therapeutics Market Cap Chart

Monte Rosa Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
- - 950.27 375.35 283.29

Monte Rosa Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 384.52 339.71 239.81 283.29 353.91

Competitive Comparison of Monte Rosa Therapeutics's Market Cap

For the Biotechnology subindustry, Monte Rosa Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Monte Rosa Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Monte Rosa Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Monte Rosa Therapeutics's Market Cap falls into.



Monte Rosa Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Monte Rosa Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$5.65*50.1402
=$283.29

Monte Rosa Therapeutics's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )=Share Price (Q: Mar. 2024 )*Shares Outstanding (EOP) (Q: Mar. 2024 )
=$7.05*50.2003
=$353.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Monte Rosa Therapeutics  (NAS:GLUE) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Monte Rosa Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Monte Rosa Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Monte Rosa Therapeutics (Monte Rosa Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
645 Summer Street, Suite 102, Boston, MA, USA, 02210
Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates.
Executives
Edmund Dunn officer: Principal Accounting Officer MONTE ROSA THERAPEUTICS, INC., 321 HARRISON AVENUE, SUITE 900, BOSTON MA 02210
Anthony M. Manning director C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Jan Skvarka director C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Philip Nickson officer: General Counsel MONTE ROSA THERAPEUTICS, INC., 40 GUEST STREET, BOSTON MA 02135
Julian G Jones officer: Chief Business Officer MONTE ROSA THERAPEUTICS, INC., 645 SUMMER STREET, SUITE 102, BOSTON MA 02210
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Joshua Makower 10 percent owner 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Versant Venture Capital Vi, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Edward T Mathers 10 percent owner C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Kimberly Blackwell director C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Cormorant Private Healthcare Fund Ii, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
New Enterprise Associates 17, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 17, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093